Literature DB >> 1736810

A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1.

D Kinchington1, S Galpin, J W Jaroszewski, K Ghosh, C Subasinghe, J S Cohen.   

Abstract

Sequences from the gag, pol and rev regions of the RF strain of HIV-1 (HIV-1RF) were chosen as targets for antisense phosphorothioate oligodeoxynucleotides (S-oligos). These sequences were the p18/p24 junction in gag, the active site of HIV protease in pol; a sequence from the first exon of the rev gene and S-oligodeoxycytidylic acid controls. Compounds were tested against HIV-1 in both acutely and chronically infected cells. The results show that these phosphorothioate analogues tested in acutely infected cells were active in the 0.1-2 microM range, were dependent on chain length but had no sequence specificity. To study the mechanism of action, the time of addition of S-oligos to acutely infected cells was delayed for up to 48 h post-infection. It was found that antiviral activity was lost when compounds were added to the cultures later than 10 h post-infection. With chronically infected cells only the antisense rev sequence showed activity at 30 microM and neither of the gag or pol antisense sequences has a significant effect on HIV replication at 50 microM. These results are consistent with previous in vitro studies which demonstrate that antisense S-oligodeoxynucleotides have several modes of action.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1736810     DOI: 10.1016/0166-3542(92)90090-r

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  9 in total

Review 1.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

2.  Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production.

Authors:  Neerja Kaushik; Amartya Basu; Paul Palumbo; Rene L Myers; Virendra N Pandey
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

Authors:  S Sei; Q E Yang; D O'Neill; K Yoshimura; K Nagashima; H Mitsuya
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 4.  Engineering T Cells to Functionally Cure HIV-1 Infection.

Authors:  Rachel S Leibman; James L Riley
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

5.  Lipid-based delivery of combinations of antisense oligodeoxynucleotides for the in vitro inhibition of HIV-1 replication.

Authors:  C Lavigne; J Yelle; G Sauvé; A G Thierry
Journal:  AAPS PharmSci       Date:  2001

6.  DNA as therapeutics; an update.

Authors:  P Saraswat; R R Soni; A Bhandari; B P Nagori
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

7.  Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.

Authors:  M A Jacobson; J Gallant; L H Wang; D Coakley; S Weller; D Gary; L Squires; M L Smiley; M R Blum; J Feinberg
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms.

Authors:  O Zelphati; J L Imbach; N Signoret; G Zon; B Rayner; L Leserman
Journal:  Nucleic Acids Res       Date:  1994-10-11       Impact factor: 16.971

Review 9.  Antisense inhibition of virus infections.

Authors:  R E Kilkuskie; A K Field
Journal:  Adv Pharmacol       Date:  1997
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.